In the best-case scenario, self-attacking T cells are ousted before they have a chance to leave the thymus. That essential process, which eliminates autoreactive thymocytes from the get-go, is known to occur in the thymic medulla. Now, on page 2575, McCaughtry et al. provide solid evidence that this elimination also occurs in the thymic cortex.
Death receptor chews up bone
Arthritis sufferers might find some relief in a new compound found to ease bone damage in mice. Bull et al. (page 2457) prevented joint erosion when they crippled a member of the TNF receptor superfamily, Death Receptor 3 (DR3), by blocking its ligand, TL1A.
Patients with rheumatoid arthritis are more likely to have extra copies of the gene that codes for DR3. A causative role for DR3 in disease pathology, however, had not been shown. Bull et al. now find that mice lacking DR3 are freed from the bone damage usually caused by antigen-induced arthritis. And blocking TL1A curtailed the bone erosion typical of collagen-induced arthritis in mice.
Back in the dish, the team investigated how this receptor-ligand pair might induce bone destruction in humans. They found that the addition of TL1A to ordinary monocytes from human blood enhanced the generation of bone-resorbing osteoclasts. Although how TL1A leads to osteoclast differentiation is not yet clear, its DR3 receptor is known to activate NFB, which is required for osteoclast formation.
A few stones remain unturned in the hunt for vandals, as obstructing TL1A didn't eliminate bone destruction altogether. Still, the researchers point out that the anti-TL1A antibody did ameliorate much of the damage.
Pain in the brain
A severe and unusual disorder often confused with multiple sclerosis (MS) has now become a little less mysterious. On page 2473, Hinson and colleagues demonstrate how the disease's distinguishing autoantibody disrupts glutamate regulation.
Neuromyelitis optica (NMO), also known as Devic's disease, results in MS-like lesions in the optic nerves and along the spine. Yet unlike MS, NMO is associated with production of a specific autoantibody known as NMO-IgG. Clinicians use NMO-IgG to diagnose the disease, but they don't know how the antibody contributes to its symptoms-sight impairment, paraplegia, and loss of limb, bladder, and bowel sensation.
In 2005, the same group identified NMO-IgG's target as aquaporin-4, a water channel protein concentrated in astrocyte membranes along the blood-brain barrier. However, the finding was somewhat perplexing because myelin damage occurs on nerve cells, not on astrocytes. Now the team confirms that astrocytes are indeed the relevant target, and show how autoantibody binding can lead to demyelination. Clue: when astrocytes hurt, their duties lapse, too.
When NMO-IgG binds to aquaporin-4, they show, the levels of the astrocyte glutamate transporter EAAT2 drop. And no transporter, no glutamate regulation. Astrocytes themselves aren't sensitive to changes in glutamate levels, but neurons and oligodendrocytes are. These cells rely on Aquaporin-4 (red) and EAAT2 (green) colocalize in normal spine.
Self-reactive thymocytes (green) are deleted in the cortex (C) before reaching the medulla (M).
Mice lacking DR3 (right) had decreased arthritic inflammation (black arrowheads) and bone erosion (blue arrowheads).
